Alopecia areata: An update

Journal of Pakistan Association of Dermatologists

Volumn 23, Issue 2, 2013, Pages 209-220

  Amin, Syed Suhail ^a   Sachdeva, Sandeep ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Alopecia areata; Etiology; Management; Pathogenesis

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BETAMETHASONE; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; METHISOPRINOL; METHYLPREDNISOLONE; MINOXIDIL; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ALOPECIA AREATA; ANAPHYLAXIS; BIOLOGICAL THERAPY; CLINICAL FEATURE; CONTACT URTICARIA; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; ERYTHEMA; ERYTHEMA MULTIFORME; EYELID EDEMA; FEVER; HAIR ANALYSIS; HAIR GROWTH; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOPIGMENTATION; LYMPHADENOPATHY; MESOTHERAPY; PRURITUS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKIN BIOPSY; VITILIGO;

EID: 84883801833     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin: Clinical Dermatology. 10th edn. Philadelphia: Saunders Elsevier; 2006.
2. Safavi KH, Muller SA, Suman VJ et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-33.
3. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35:22-7.
4. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405-9.
5. Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Invest Dermatol Symp Proc. 2004;9:73-8.
6. Brenner R. Coincidences of alopecia areata, vitiligo, onychodystrophy, localized scleroderma and lichen planus. Dermatologica. 1979;159:356-8.
7. Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42:434-7.
8. Trueb RM. Systematic approach to hair loss in women. Indian Clin Updates-Dermatology 2010;2:284-97.
9. Paus R. Control of the hair cycle and hair diseases as cycling disorders. Curr Opin Dermatol. 1996;3:248-58.
10. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007;46:121-31.
11. Tosti A, La Placa M, Placucci F et al. No correlation between cytomegalovirus and alopecia areata. J Invest Dermatol. 1996;107:443.
12. Yang S, Yang J, Liu JB et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol. 2004;151:16-23.
13. McMichael AJ. The genetic epidemiol autoimmune pathogenesis alopecia areata. J Eur Acad Dermatol Venereol. 1997;9:36-43.
14. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405-9.
15. Kavak A, Baykal C, Ozarmagan G, Akar U. HLA in alopecia areata. Int J Dermatol. 2000;39:598-92.
16. Barahmani N, de Andrade M, Slusser JP et al. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006;126:74-8.
17. Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73-8.;
18. Gilhar A, Kalish R. Alopecia areata: a tissue-specific autoimmune disease of the hair follicle. Autoimmunity Rev. 2006;5:64-9.
19. Tan E, Tay Y-K, Goh CL et al. The pattern of alopecia areata in Singapore - a study of 219 Asians. Int J Dermatol. 2002;41:748-53.
20. Tan E, Tay YK, Giam YC. A clinical study of childhood alopecia areata in Singapore. Pediatric Dermatol. 2002;19:298-301.
21. Camacho F. Alopecia areata. Clinical characteristics and dermatopathology, in Trichology: diseases of the pilosebaceous follicle 1997, Madrid, Aula Medical Group, S. A. 471-440.
22. Zoe Diana Draelos (August 30, 2007), Alopecia Areata. MedicineNet.com. Retrieved on May 11, 2011.
23. Cline DJ. Changes in hair color. Dermatol Clin. 1988;6:295-303.
24. Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011;24:348-54.
25. Olsen EA. Hair. In: Freedberg IM, editors. Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill; 2003. P.641-3.
26. Olsen EA, Hordinsky MK, Price VH et al. National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines. part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440-7.
27. Price VH, Gummer CL. Loose anagen syndrome. J Am Acad Dermatol. 1989;20:249-56.
28. Lew B-L, Shin M-K, Sim W-Y. Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol. 2009;60:85-93.
29. Garcia-Hernandez MJ. CFM. Atypical clinical forms of alopecia areata. In: Camacho Francisco MR, Price Vera H, eds. Hair and its Disorders: Biology, Pathology, and Management. London: Martin Dunitz; 2000. P.228-31.
30. Ragunatha S, Inamadar AC, Palit A et al. Diffuse nonscarring alopecia of scalp: an indicator of early infantile scurvy? Pediatr Dermatol. 2008;25:644-6.
31. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139:1555-9.
32. Igarashi R, Moroashi M, Takeuchi S. Immunofluorescence studies on complement components in the hair follicles of normal scalp and of scalp affected by alopecia areata. Acta Derm Venreo.l 1981;61:131-5.
33. Shimmer BP, Parker KL, eds. Goodman's and Gillman's: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001. P.1661-3.
34. Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23:227-43.
35. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-66.
36. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy, side effects including histologic study ensuing localized acneiform response. Dermatologica. 1970;141:193-202.
37. Tosti A, Piraccini BM, Pazzaglia M et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96-8.
38. Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol. 1975;55:493-6.
39. Friedli A, Labarthe MP, Engelhardt E et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol. 1998;39:597-602.
40. Pasricha JS, Kumrah L. Alopecia totalis treated with oral mini-pulse (OMP) therapy with betamethasone. Indian J Dermatol Venereol Leprol. 1996;62:106-9.
41. Dickerman RD, Jaikumar S. The hiccup reflex arc and persistent hiccups with high dose anabolic steroids: Is the brainstem the steroid-responsive locus? Clin Neuropharmacol. 2001;24:62-4.
42. Fiedler VC, Wendrow A, Szpunar GJ et al. Treatment resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol. 1990;126:756-9.
43. Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol. 1991;96:73S-74S.
44. Fransway AF, Muller SA. 3 Percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. Cutis. 1988;41:431-5.
45. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16:730-6.
46. Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23:227-43.
47. Thappa DM, Vijayikumar M. Alopecia areata. Indian J Dermatol Venereol Leprol. 2001;67:187-90.
48. Rosenberg EW, Drake L. In: Discussion of Dunaway DA. Alopecia areata. Arch Dermatol. 1976;112:256.
49. Van der Steen PH, van Baar HM, Happle R et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol. 1991;24:227-30.
50. Happle R, Echternacht K. Induction of hair growth in alopecia areata with DNCB. Lancet. 1977;2:1002-3.
51. Galbraith GMP, Thiers BH, Fundenberg HH. An open-label trial of immunomodulation therapy with Inosiplex (Isoprinosine) in patients with alopecia totalis and cell mediated immunodeficiency, J Am Acad Dermatol. 1984;11:224-30.
52. Whitmont K, Cooper A. PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol. 2003;44:106-9.
53. Mohamed Z, Bhouri A, Jallouli A et al. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol Venereol. 2005;19:552-5.
54. Sharma PK, Jain RK, Sharma AK. PUVASOL therapy in alopecia areata. Indian J Dermatol Venereol Leprol. 1990;56:301-3
55. Taylor M, Ashcroft AT, Messenger AG. Cyclosporin A prolongs human hair growth in vitro. J Invest Dermatol. 1993;100:237-9.
56. Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339-50.
57. Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatol Ther. 1998;5:74-84.
58. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol. 1994;102:160-4.
59. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol 1995;104:523-5.
60. Ellis CN, Brown MF, Voorhees JJ. sulfasalazine for alopecia areata. J Am Acad Dermatol. 2002;46:541-4.
61. Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47:850-2.
62. Olsen AE. Female pattern hair loss. J Am Acad Dermatol. 2001;45:S70-80.
63. Strober B, Siu K, Alexis A et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52:1082-4.